Research Analysts Set Expectations for BDTX FY2024 Earnings

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond Therapeutics in a report released on Tuesday, November 5th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($1.29) per share for the year, up from their prior forecast of ($1.44). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.31) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.33) EPS and FY2025 earnings at ($1.28) EPS.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.09.

A number of other analysts also recently issued reports on BDTX. Wedbush reissued an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research report on Tuesday, October 8th. Raymond James started coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price target for the company. Finally, Piper Sandler boosted their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd.

Black Diamond Therapeutics Stock Up 3.5 %

Shares of BDTX stock opened at $3.29 on Friday. The firm has a market cap of $185.92 million, a P/E ratio of -2.19 and a beta of 2.51. The company has a 50 day moving average of $4.10 and a 200-day moving average of $5.00. Black Diamond Therapeutics has a 12-month low of $1.62 and a 12-month high of $7.66.

Institutional Investors Weigh In On Black Diamond Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. purchased a new position in shares of Black Diamond Therapeutics in the third quarter valued at $68,000. Susquehanna Fundamental Investments LLC bought a new position in Black Diamond Therapeutics in the 1st quarter worth about $82,000. SG Americas Securities LLC purchased a new position in Black Diamond Therapeutics during the 2nd quarter valued at about $108,000. Algert Global LLC purchased a new position in Black Diamond Therapeutics during the 2nd quarter valued at about $133,000. Finally, Rhumbline Advisers increased its position in shares of Black Diamond Therapeutics by 10,334.3% during the second quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock valued at $218,000 after buying an additional 46,401 shares during the period. Hedge funds and other institutional investors own 95.47% of the company’s stock.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.